Paul Richardson

Paul Richardson has been central to the clinical development of proteasome inhibitors including bortezomib, carfilzomib, and ixazomib in multiple myeloma. He led pivotal trials that established these agents as cornerstones of myeloma therapy. His research has focused on understanding mechanisms of proteasome inhibitor resistance and developing strategies to overcome them. He has been a key investigator in numerous Phase 3 trials that have defined standards of care in myeloma.